Pacira reported $950.8M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Astellas Pharma JPY 215.29B 225M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.25B 168M Sep/2026
Ligand Pharmaceuticals USD 72.62M 43.49M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 950.8M 858.99M Sep/2026
Perrigo USD 271.7M 3.01B Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026
Xeris Pharmaceuticals USD 61.04M 7.89M Jun/2026
Zoetis USD 582M 10M Sep/2026